Clinical Trial Update: Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial comparing celecoxib added to R-CHOP versus R-CHOP alone in newly diagnosed CD5-positive diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Celecoxib (Celecoxib)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | Phase 2 | Status: NOT_YET_RECRUITING